Seattle Genetics, Inc. Reports Preclinical Data On Its SGN-40 And SGN-70 Programs At The American Society Of Hematology Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) reported preclinical data from its SGN-40 and SGN-70 programs at the American Society of Hematology (ASH) 2005 Annual Meeting being held in Atlanta December 10-13. Preclinical studies of SGN-40 demonstrated broad application in B-cell malignancies, including Hodgkin’s disease and chronic lymphocytic leukemia, and in combination with lenalidomide (Revlimid(R)). Preclinical studies of SGN-70 have shown that it has therapeutic potential in hematologic malignancies.